{"ticker": {"uuid": "dd75868f-fa2d-42b1-bea9-c24272033f93", "symbol": "ACRS", "name": "Aclaris Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris", "summary": "DelveInsight's report details the Vitiligo pipeline for 2026, highlighting over 20 companies developing more than 25 treatment therapies. The report covers clinical development phases from pre-clinical to marketed stages, including recent clinical trial advancements and FDA appro", "url": "https://www.barchart.com/story/news/3173291/vitiligo-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-dermira-amgen-pfizer-dermavant-sciences-incyte-twi-biotechnology-aclaris", "source_name": "Barchart.com", "published_at": "2026-07-07T22:11:22", "published_display": "07 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOa01nTGNSYVZ1c2lBaUMyUlpGcExMd1RMWV9nWXNrNUkwdVNKVXBRRHlwZFp1VDNSNHpTNG83NW5LM3JZRkNGTjFveWJ4VWxlMTI2U25qOU5NcnNqRDJfNHNraDhiQUczMk1sZFh5X0liYmdjeUlIWmJuRjJOeldWblU5SFJ1Rm50TTVIX0lLUjlFeUV2NjczNQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark", "summary": "Aclaris Therapeutics, Inc. (NasdaqGS: ACRS) has been included in the Russell 2500 Growth Benchmark. This addition highlights the company's growth trajectory and increased visibility within the financial markets. The article also provides recent news and a company profile, detaili", "url": "https://www.marketscreener.com/news/aclaris-therapeutics-inc-nasdaqgs-acrs-added-to-russell-2500-growth-benchmark-ce7f5fdfda81fe2c", "source_name": "marketscreener.com", "published_at": "2026-06-29T19:28:04", "published_display": "29 Jun 2026 19:28", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast, price target, and prediction for Aclaris Therapeutics, Inc. (ACRS) stock. It includes analyst ratings, historical price data, financial metrics such as EPS, revenue, net income, and EBITDA, along with future earnings and revenue estimates. Invest", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T00:39:27", "published_display": "29 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "This article provides the \"Price to sales forward\" metric for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). The content outlines the company's financial data, accessible through TradingView, a platform offering various financial tools and market data for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:52", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQYTJ0Qmc3M0c5QTY0cUdPdlRuV3N2bjVPejRJTzhVRGR0cDF3OHY3MGRUUEJ5VWg5QTh6VGc5S1RlVkVqcmFpRXd0b0V0OUxNRGROcmNIb1otZHJYLVUxMTdscnZHSkQ3cDhldDFPQXk4LTlvTGEya0xvaEg1WlpaQy1sYm1VUVUySEsyNnpuNW14Z0twODZqY2JhUFdGWjF6VnVqYzc5U0V1c1pBQzlvTV8wS3ZYWjVMdmJoeS1lM0h0RGpyS0hEWExKNkdDcmFzcGplYjdHdw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. \u2013 DUS:8AT", "summary": "This article provides financial information for Aclaris Therapeutics, Inc. (DUS:8AT) on TradingView, specifically focusing on its enterprise value to EBIT forward metric. The content indicates that for the period, the value, change, and percentage change were \"No trades.\" The inf", "url": "https://www.tradingview.com/symbols/DUS-8AT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:10:53", "published_display": "28 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "This article provides a brief mention of the \"Price to book forward\" metric for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). It is presented within the context of financial data available on TradingView, indicating that the value for this metric is displayed alongside a change and ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:39", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aclaris Therapeutics, Inc. \u2013 DUS:8AT", "summary": "This page provides financial information for Aclaris Therapeutics, Inc. (8AT) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content indicates that the market is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/DUS-8AT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:41:04", "published_display": "27 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNMVlmM2poeXBSN1hTTTlLQzVHYWZKMXd4MGFVYkhmZk5tbW1ValBnYVlpR3lOV0ZScktIRnFTdlpfbVRZUDI0S1YyV1ZWeUJwVkhtS3dyWGJjNUF0RkhxUm9zSGRxbUY5alVBZ0Y5c1FQTXNMVEgzU1BIX2htWUw0bkpiZUNNU3VwbjE4bjAtVUZlVGg4STFxeF9VRlltS0lQYmc?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T16:18:58+00:00", "published_display": "27 Jun 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "This article provides the enterprise value to EBITDA forward for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). It briefly details the company's stock information and acknowledges that market data is provided by ICE Data Services and FactSet. The content is primarily a data point wit", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:11:24", "published_display": "27 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS)", "summary": "This article provides an overview of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It also includes information on the company's market capitalization, earnings reports, revenue,", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:24", "published_display": "26 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcE9SZHlyZVU2T3A0X1p1cDdGMVJoVDZGRGJRSy1VZEp6aEkteDVpcFdMc2wxdUp4VmdYXzN3TlROZG1TOU1EVFVhZzZ4M0JpaWRIMi05SU51cTRWOHZFSWI5MEJ1R1VfQVVZQXhsdjRwMUNQcmdSUy1ZNTRCYWkya0MzSm5OZUJ0ZUVodW00MTVhbHZIcXhPYzBLT0xOTEt0SUNnS2t3?oc=5", "source_name": "Moomoo", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index", "summary": "Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) has been added to the S&P Pharmaceuticals Select Industry Index. The company is a clinical-stage biopharmaceutical firm focused on developing product candidates for immuno-inflammatory diseases, utilizing its proprietary KINect drug disc", "url": "https://www.marketscreener.com/news/aclaris-therapeutics-inc-nasdaqgs-acrs-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df624", "source_name": "www.marketscreener.com", "published_at": "2026-06-21T21:27:00", "published_display": "21 Jun 2026 21:27", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Aclaris Therapeutics Inc (ACRS) on TradingKey. It indicates that ACRS has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also displays current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:32", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Aclaris Therapeutics Inc (ACRS), highlighting its current valuation score of 7.88 and its ranking within the Biotechnology & Medical Research industry. It notes the company's P/E ratio of -8.03, which is significantly below its recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:03", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Aclaris Therapeutics Inc (ACRS), outlining both major individual shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and a list of active ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:39", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Aclaris Therapeutics Inc (ACRS), focusing on its business segments. As of April 6, the company's revenue is primarily derived from Licensing (76.08%, $5.95M) and Laboratory Research Revenue (23.92%, $1.87M). The report indica", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:39", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Aclaris Therapeutics Inc (ACRS) has an earnings forecast score of 8.91, ranking 36th in its industry, with an average analyst price target of $7.00. Analysts largely recommend a \"Buy\" for ACRS stock, with a projected upside of over 110%. The company's expected revenue for the nex", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:39", "published_display": "17 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS - Aclaris Therapeutics Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news for Aclaris Therapeutics Inc (ACRS). It details the company's current stock price, market capitalization, earnings per share, insider and institutional ownership, and a", "url": "https://finviz.com/stock?t=ACRS", "source_name": "Finviz", "published_at": "2026-06-12T12:11:04", "published_display": "12 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) director gains new RSUs and stock options", "summary": "Aclaris Therapeutics director Maxine Gowen received 10,987 Restricted Stock Units and a stock option for 42,350 shares on June 4, 2026. On June 5, 2026, 11,580 RSUs vested, converting to common stock, leaving her with 33,334 direct common shares. This activity represents equity c", "url": "https://www.stocktitan.net/sec-filings/ACRS/form-4-aclaris-therapeutics-inc-insider-trading-activity-b1d8fa49be37.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:40:55", "published_display": "09 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant", "summary": "Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation, including the vesting of 11,580 restricted stock units (RSUs) which converted into common stock on June 5, 2026, increasing his direct holdings to 25,540 shares. He also received new grants on Ju", "url": "https://www.stocktitan.net/sec-filings/ACRS/form-4-aclaris-therapeutics-inc-insider-trading-activity-a0d8ad26d955.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:48", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On", "summary": "Stifel has reiterated a Hold rating and increased the price target for Aclaris Therapeutics Inc. (ACRS) to $4, citing optimism about its multi-targeting approaches and immunology biology. The company is developing best-in-class compounds for immunological diseases, with positive ", "url": "https://www.insidermonkey.com/blog/aclaris-therapeutics-inc-acrs-a-top-penny-stock-in-investors-portfolio-that-stifel-is-bullish-on-1776514/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-07T17:39:03", "published_display": "07 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052", "summary": "Aclaris Therapeutics is planning a busy period for its drug pipeline, highlighted by the upcoming phase 2 clinical trial for its investigational drug ATI-052 in asthma patients. This advancement indicates the company's focus on developing new treatments and expanding its therapeu", "url": "https://www.msn.com/en-us/health/other/aclaris-therapeutics-maps-busy-pipeline-calendar-plans-phase-2-asthma-trial-for-ati-052/ar-AA24RxAc", "source_name": "MSN", "published_at": "2026-06-07T00:10:08", "published_display": "07 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC", "summary": "Aclaris Therapeutics, Inc. (NASDAQ: ACRS) held its 2026 annual meeting where shareholders re-elected two directors, Anand Mehra, M.D. and Maxine Gowen, Ph.D., to serve until the 2029 annual meeting. They also approved the compensation of the company\u2019s named executive officers on ", "url": "https://www.stocktitan.net/sec-filings/ACRS/8-k-aclaris-therapeutics-inc-reports-material-event-63b2c783ee08.html", "source_name": "Stock Titan", "published_at": "2026-06-05T12:10:22", "published_display": "05 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital", "summary": "LifeSci Capital has set a price target of $13.00 per share for Aclaris Therapeutics (NASDAQ: ACRS). This announcement provides investors with an analyst's valuation perspective on the biopharmaceutical company. Investors may consider this price target in their evaluation of Aclar", "url": "https://www.moomoo.com/news/post/70947668/aclaris-therapeutics-price-target-announced-at-13-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-03T09:40:39", "published_display": "03 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform'", "summary": "LifeSci Capital initiated coverage on Aclaris Therapeutics (ACRS) with an 'Outperform' rating and a $13.00 price target, signaling a positive outlook for the biopharmaceutical company. Despite this, GuruFocus assesses ACRS as significantly overvalued with a GF Value\u2122 of $0.46 aga", "url": "https://www.gurufocus.com/news/8896767/acrs-initiated-coverage-by-lifesci-capital-rating-outperform?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-03T03:40:39", "published_display": "03 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 PM ET. CEO Dr. Neal Walker and other senior leaders will host a fireside chat, which will be webcast live and archived on the company'", "url": "https://investingnews.com/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference/", "source_name": "Investing News Network", "published_at": "2026-05-28T14:39:39", "published_display": "28 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $10.2, Implies 126% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNdzB2TmtSZHE2am1aWlZJV1prbXlPNkdHdFk2M2Nid2JQekJUOXBnSk9lNmNuMkhnaEFHSEhNOXhjNkZfTktIYjJuQXl0LVJVdl95b3QzU2RWRDJyeGFnREgtaUVmdm9MUkZteXNVRGo0dXB1bEZYYUlpSThJUW9BMWo1M2Uyc2NnbUN3dUV2aGFFdjZER2piWHRFSVhnRjFLNFFiVjYwNFppSFV0X29tbVB6LWE2QUh0Zzlib0FPQUp3cGRqck8tRjRnNFhBNnZsSlBtVEdocmFwM1JzOFpKYUNR?oc=5", "source_name": "TradingView", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Expands Immunology Pipeline Ahead of Key Trial Data", "summary": "Aclaris Therapeutics (Nasdaq: ACRS) is advancing its immunology pipeline with several mid- and late-stage clinical milestones expected this year. The company anticipates topline data for ATI-052 in asthma and atopic dermatitis and bosakitug in atopic dermatitis in the second half", "url": "https://www.mychesco.com/a/news/business/aclaris-expands-immunology-pipeline-ahead-of-key-trial-data/", "source_name": "MyChesCo", "published_at": "2026-05-16T16:40:11", "published_display": "16 May 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding", "summary": "Aclaris Therapeutics, Inc. (ACRS) is advancing multiple late-stage immunology assets, including biologics and small molecules targeting dermatologic and respiratory diseases, towards key milestones in 2024. The company's pipeline features anti-TSLP and ITK inhibitors, and it expe", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3330427:0-acrs-multiple-late-stage-immunology-assets-advance-toward-key-2024-milestones-backed-by-robust-funding/", "source_name": "TradingView", "published_at": "2026-05-14T17:09:09", "published_display": "14 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026", "summary": "Aclaris Therapeutics (ACRS) is progressing three novel compounds through clinical trials, targeting significant, underserved inflammatory and immunological (I&I) markets. These compounds, comprising both oral and biologic therapies, have demonstrated strong efficacy and safety. M", "url": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3330220:0-acrs-multiple-innovative-i-i-therapies-advance-toward-key-phase-2b-milestones-in-2026/", "source_name": "TradingView", "published_at": "2026-05-14T16:09:09", "published_display": "14 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQYjRlcEoycDlIYzhLOWFxLUxRbFJxdE9OUktSU0gzVENaVGZNSzhUQWF4eHltQXRZb3hDSm12amVrdkFFd2J6dHNZTFRuelc4b3JPdU1uRlVwZ0xmQzZpSDZHTzBlbDNtVHpxdV9wZ3ljdjBsUHBRLVF6VHNNQm5KZlh6MWZNNkw4ZHJDT2w0Z25KRWpUWkQ0V1JycWtKMkhzdkYtUjlMRkY0ZjhJVmhhSw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) Quarterly Loss Near US$20 Million Reinforces Bearish Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aclaris-q1-earnings-snapshot-110757979.html", "source_name": "Associated Press", "published_at": "2026-05-07T11:07:57+00:00", "published_display": "07 May 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aclaris-therapeutics-reports-first-quarter-105900970.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T10:59:00+00:00", "published_display": "07 May 2026 10:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNXpFU2NzVTR5bXNLTVN5em4yR0V6UGtEaU5vTlhhdUQtbElvUV9iQWhZdHhFQ2ZVSGZMWWhpMWNrNE1LaEVpWDF5cEdkcUkwLVNnY2pETFA1VlFkSWNXYVdvdmNBTnJUbktOWXNFVm5UdWtjRGZ1Z0N1T0t3dU9PNUZDb0h4QkhYSmY1N2FvMm1BaF9TcDU4QXBXc0dqb3dVZFoxVXJkWGQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSzVOeENvM1lfUjkwUUhoMExmcXlxWmUtS1U3OGVWWWdOWFk1VDVNUzg2XzRkVV8xUVZvVVRMZFVXNkxxaEY4ZGRzWEdEZHNVSURCb0hxYXJkUGRiOElaY1hya2lfMC1icFcycHNRTm1JWVlaSEZNXzNNaVdsdGZlU1FGNDM5cXp0THBQRmRKRHV2NmtuaFhUQ29PUkg1LWJtcTNOamNhRjhTMnM?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQMUhVbVluZFRzUG1XZUhZaFJOX0lEVkV0d2tUeE92Tl9haDBqWUx0eEVDUGRING1RSUEwUUVpZEtfX0syeGhRSHlKbm1sUS1leW5Md0FSNWo2cENrQm95bXdTRFVsdWp1TGtUdFlmTW5oWEFLWDZTcnUwQ24zOUZEMDlZdE9wZHVrMDhMcGV0em1zZDBuNHVZTDNoX2IxNzZjZHBQN05tSjZ5WnZvQTJ0STJhMkx1ejYtWWFRbE9kSldoZkZVSV93?oc=5", "source_name": "Investing.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of Life", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxOTDdZekxqRzcxeXNGeE13cFkxZkRLVklHaWZDWUYxcXJ4M3MwRXFaZkU4T2RNYXh4WG0tV1E2UDRpRDA5Qm10dy0zTFkwY1J6QW1RbnFoOFJJRGRQQXBsUXFrRXNWSS1iSXNqejNpczM1Znl4MDBPdm5CcXJzSU5ZNW5uUjZQSkJ1Z0hhYjVkRTZFVW5GdmRycERRTXVDREZiN3RBRE9QbUM5c21kYnlqdnBabEUtbWtrbXAwT29WRFM1SVphVVdfY0xfUFFsWGYzVHlaT29hSmtpcDNyM044UDg0WUxsQUtvU2ZhYXpPNXlVbmVSYi10ZnpzVVhRX0xJVkdxY2pUMVRNMXJtbDhYXzhUMEFxbkVHNkw2bWVWTXhTRTU2Nm9wNHRGMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNS0d2RWJVMk9CSFJCdXlNVV9Rb1pPYmdDQWl4N3R3Mi1nUEZUbmV3MGlMRzhmeDR6aFVONWNYT2tGcU1fd01Pb2VYQnJrMHVzdE42Rjg5akI0aUFOTUlMUV9LZGRUYXc5NDVNelBRV3hUS2NLcDJKdk5YVUtYVTlRbkVwcw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOU05hb29UajNidmlUNHdLMElpaW8zcDRleFN2Q0ZPY0tYN21OdEFpN1hfZEhaV0xNTllLWjlBQVFSWW9mdkFKdU1XeWVuV0pjTTNkMU5OcmlES3FrZzJ3RlNxYi1hLUVlTWV4bEVBdlVvSm0tc2dnckN2WjllMWdLSkRkUWNWZHU5LXlnUkNodWQyMU5DTVlsQlhIcWZiZldlQzdtRHhPU1JaSWdWV013TFRGa1pMM3Y3Y1dCZUE4aDhQNDc3Z092RWJR?oc=5", "source_name": "TradingView", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow (NASDAQ:ACRS) 2026-01-06", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNT3NrbTdaSTI2allPYzhCSlpWUy1WSTI2QkRqekVXRDVPbURHb3Jyb1FOT1h5WTRiaUFORkZqTVhmckVmaXFZc3FxT1NZcDNMN0RmSkFNOW9XV25vMzUwcEktbnQ2Sk90RHY0NjI2cGNZQWVPeWwwTGVqeUJYYWEtZHhQZ3lmN0FoRWJISE5Ccjg5VFVDNTN2MGdMWmFqemFGUmNXU1lXUV8wQ2oweGRwWnVOSFZTZkYzNmYwNjI2dlhiTXZxVWRLV0k4b3o?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Aclaris Therapeutics Stock Hold Up When Markets Turn?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOT3ZhcmxlQnVtWXc1dmdmWnJqNUVIR0JTSTY5RjVUeUxCcVYwNHdUQ0VaVzhXZHVGODdNRjZwaVBtZ3Q4eE5EMlotRzV0TFdXUXBaY1E2MHBmc2pGak9KTFZwWEY1anBmVzAtVUZUOUM2MTdEcHhWeGtlMlJFNXhsc3ZjcmM4ZkpyVElMQkd2OXVyeFNVSllrM1pBX3R5bGpOZW9ZMjFoc0dLTnQ5ZDkyeHhQZ09tN1l0bDBDcVFncUlqM01SdlE?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPVXdwXzdtVVFQeW5ld2d6Q00xZ0ZIV1pFZW11eDB1STM1ZFNBLThIZjNDRmZRY1RGdzl5QXlxVXlpTVY2UVdWLUJBdHgxd2p3QkdYRU12QlpVd1RoTHdyVUtDS2tvVXpoS2JqaUJSZXQxSDFBcXhfY2RtTmtzb3YtMlNWUlFfQzJ6QUlDbktDOWpFNUJNbFNSc0xRX0JiZVpTbmVsMmFLdkRQNDhZZzZJZS11VFhZZjlRWW52NlFVbDVNTm9PblhjU3E5Z01oVmFSWldRRXIzZWRJanU2Qk1j?oc=5", "source_name": "BioPharma APAC", "published_at": "2024-11-19T08:00:00+00:00", "published_display": "19 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Secures $80 Million in Private Placement of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOdEVOTW9CRGQ0NE5yTWNrQTBEUElCc3ZFQTJuTjl0aEJGcWZJSnFzTmlRajltcFV2enJHZ2EwZmRMcTZLdGpzZl93TUFYcFJCMVlZTDZqb19rLVUtQUJYSThqMEV0OVgxajJELVU2UVRLU3lBNWMxSjlUN0Y3ejk4VmIyT25QTkRqcExBTjNfb3VsY2RRRzJWZ3R1WDYtbV9GTWVieVpBTFY1UFN6UlNTa01n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-11-18T08:00:00+00:00", "published_display": "18 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS Stock Price and Chart \u2014 NASDAQ:ACRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1VUWlFQzNzcGo1N1R0THFMSWZVWnpLTFVKV2JaYjVsZnVEM1VDSVJlLXNWN3JnNkRucjMxdU1nNFd1dUliSnhaR1Q3aUQ4RDVBWXdERDFUZ0lacjJz?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T08:30:47+00:00", "published_display": "21 Jul 2017 08:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $ACRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE14cHlpejJyY2hZam9razF1NXVpZGZpdFBoMXdtS3dEREhaR2dlWUJmSGhUa0tjMUprRERab3MwZUZaUlBqamZLbzhja0ZQQzZ1TmdfMHdtZkk5Zw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T01:44:29+00:00", "published_display": "12 Aug 2016 01:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris", "summary": "DelveInsight's report details the Vitiligo pipeline for 2026, highlighting over 20 companies developing more than 25 treatment therapies. The report covers clinical development phases from pre-clinical to marketed stages, including recent clinical trial advancements and FDA appro", "url": "https://www.barchart.com/story/news/3173291/vitiligo-pipeline-2026-therapies-under-investigation-clinical-trials-milestones-and-fda-approvals-by-delveinsight-dermira-amgen-pfizer-dermavant-sciences-incyte-twi-biotechnology-aclaris", "source_name": "Barchart.com", "published_at": "2026-07-07T22:11:22", "published_display": "07 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOa01nTGNSYVZ1c2lBaUMyUlpGcExMd1RMWV9nWXNrNUkwdVNKVXBRRHlwZFp1VDNSNHpTNG83NW5LM3JZRkNGTjFveWJ4VWxlMTI2U25qOU5NcnNqRDJfNHNraDhiQUczMk1sZFh5X0liYmdjeUlIWmJuRjJOeldWblU5SFJ1Rm50TTVIX0lLUjlFeUV2NjczNQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark", "summary": "Aclaris Therapeutics, Inc. (NasdaqGS: ACRS) has been included in the Russell 2500 Growth Benchmark. This addition highlights the company's growth trajectory and increased visibility within the financial markets. The article also provides recent news and a company profile, detaili", "url": "https://www.marketscreener.com/news/aclaris-therapeutics-inc-nasdaqgs-acrs-added-to-russell-2500-growth-benchmark-ce7f5fdfda81fe2c", "source_name": "marketscreener.com", "published_at": "2026-06-29T19:28:04", "published_display": "29 Jun 2026 19:28", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast, price target, and prediction for Aclaris Therapeutics, Inc. (ACRS) stock. It includes analyst ratings, historical price data, financial metrics such as EPS, revenue, net income, and EBITDA, along with future earnings and revenue estimates. Invest", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T00:39:27", "published_display": "29 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "This article provides the \"Price to sales forward\" metric for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). The content outlines the company's financial data, accessible through TradingView, a platform offering various financial tools and market data for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:52", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQYTJ0Qmc3M0c5QTY0cUdPdlRuV3N2bjVPejRJTzhVRGR0cDF3OHY3MGRUUEJ5VWg5QTh6VGc5S1RlVkVqcmFpRXd0b0V0OUxNRGROcmNIb1otZHJYLVUxMTdscnZHSkQ3cDhldDFPQXk4LTlvTGEya0xvaEg1WlpaQy1sYm1VUVUySEsyNnpuNW14Z0twODZqY2JhUFdGWjF6VnVqYzc5U0V1c1pBQzlvTV8wS3ZYWjVMdmJoeS1lM0h0RGpyS0hEWExKNkdDcmFzcGplYjdHdw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. \u2013 DUS:8AT", "summary": "This article provides financial information for Aclaris Therapeutics, Inc. (DUS:8AT) on TradingView, specifically focusing on its enterprise value to EBIT forward metric. The content indicates that for the period, the value, change, and percentage change were \"No trades.\" The inf", "url": "https://www.tradingview.com/symbols/DUS-8AT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:10:53", "published_display": "28 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "This article provides a brief mention of the \"Price to book forward\" metric for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). It is presented within the context of financial data available on TradingView, indicating that the value for this metric is displayed alongside a change and ", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:39", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aclaris Therapeutics, Inc. \u2013 DUS:8AT", "summary": "This page provides financial information for Aclaris Therapeutics, Inc. (8AT) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content indicates that the market is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/DUS-8AT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:41:04", "published_display": "27 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNMVlmM2poeXBSN1hTTTlLQzVHYWZKMXd4MGFVYkhmZk5tbW1ValBnYVlpR3lOV0ZScktIRnFTdlpfbVRZUDI0S1YyV1ZWeUJwVkhtS3dyWGJjNUF0RkhxUm9zSGRxbUY5alVBZ0Y5c1FQTXNMVEgzU1BIX2htWUw0bkpiZUNNU3VwbjE4bjAtVUZlVGg4STFxeF9VRlltS0lQYmc?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T16:18:58+00:00", "published_display": "27 Jun 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. \u2013 NASDAQ:ACRS", "summary": "This article provides the enterprise value to EBITDA forward for Aclaris Therapeutics, Inc. (NASDAQ: ACRS). It briefly details the company's stock information and acknowledges that market data is provided by ICE Data Services and FactSet. The content is primarily a data point wit", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:11:24", "published_display": "27 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS)", "summary": "This article provides an overview of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It also includes information on the company's market capitalization, earnings reports, revenue,", "url": "https://www.tradingview.com/symbols/NASDAQ-ACRS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:24", "published_display": "26 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQcE9SZHlyZVU2T3A0X1p1cDdGMVJoVDZGRGJRSy1VZEp6aEkteDVpcFdMc2wxdUp4VmdYXzN3TlROZG1TOU1EVFVhZzZ4M0JpaWRIMi05SU51cTRWOHZFSWI5MEJ1R1VfQVVZQXhsdjRwMUNQcmdSUy1ZNTRCYWkya0MzSm5OZUJ0ZUVodW00MTVhbHZIcXhPYzBLT0xOTEt0SUNnS2t3?oc=5", "source_name": "Moomoo", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index", "summary": "Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) has been added to the S&P Pharmaceuticals Select Industry Index. The company is a clinical-stage biopharmaceutical firm focused on developing product candidates for immuno-inflammatory diseases, utilizing its proprietary KINect drug disc", "url": "https://www.marketscreener.com/news/aclaris-therapeutics-inc-nasdaqgs-acrs-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df624", "source_name": "www.marketscreener.com", "published_at": "2026-06-21T21:27:00", "published_display": "21 Jun 2026 21:27", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Aclaris Therapeutics Inc (ACRS) on TradingKey. It indicates that ACRS has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also displays current stock p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:32", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Aclaris Therapeutics Inc (ACRS), highlighting its current valuation score of 7.88 and its ranking within the Biotechnology & Medical Research industry. It notes the company's P/E ratio of -8.03, which is significantly below its recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:03", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Aclaris Therapeutics Inc (ACRS), outlining both major individual shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and a list of active ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:39", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Aclaris Therapeutics Inc (ACRS), focusing on its business segments. As of April 6, the company's revenue is primarily derived from Licensing (76.08%, $5.95M) and Laboratory Research Revenue (23.92%, $1.87M). The report indica", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:39", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Inc (ACRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Aclaris Therapeutics Inc (ACRS) has an earnings forecast score of 8.91, ranking 36th in its industry, with an average analyst price target of $7.00. Analysts largely recommend a \"Buy\" for ACRS stock, with a projected upside of over 110%. The company's expected revenue for the nex", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-acrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:39", "published_display": "17 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS - Aclaris Therapeutics Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news for Aclaris Therapeutics Inc (ACRS). It details the company's current stock price, market capitalization, earnings per share, insider and institutional ownership, and a", "url": "https://finviz.com/stock?t=ACRS", "source_name": "Finviz", "published_at": "2026-06-12T12:11:04", "published_display": "12 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) director gains new RSUs and stock options", "summary": "Aclaris Therapeutics director Maxine Gowen received 10,987 Restricted Stock Units and a stock option for 42,350 shares on June 4, 2026. On June 5, 2026, 11,580 RSUs vested, converting to common stock, leaving her with 33,334 direct common shares. This activity represents equity c", "url": "https://www.stocktitan.net/sec-filings/ACRS/form-4-aclaris-therapeutics-inc-insider-trading-activity-b1d8fa49be37.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:40:55", "published_display": "09 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant", "summary": "Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation, including the vesting of 11,580 restricted stock units (RSUs) which converted into common stock on June 5, 2026, increasing his direct holdings to 25,540 shares. He also received new grants on Ju", "url": "https://www.stocktitan.net/sec-filings/ACRS/form-4-aclaris-therapeutics-inc-insider-trading-activity-a0d8ad26d955.html", "source_name": "Stock Titan", "published_at": "2026-06-08T23:39:48", "published_display": "08 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On", "summary": "Stifel has reiterated a Hold rating and increased the price target for Aclaris Therapeutics Inc. (ACRS) to $4, citing optimism about its multi-targeting approaches and immunology biology. The company is developing best-in-class compounds for immunological diseases, with positive ", "url": "https://www.insidermonkey.com/blog/aclaris-therapeutics-inc-acrs-a-top-penny-stock-in-investors-portfolio-that-stifel-is-bullish-on-1776514/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-07T17:39:03", "published_display": "07 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052", "summary": "Aclaris Therapeutics is planning a busy period for its drug pipeline, highlighted by the upcoming phase 2 clinical trial for its investigational drug ATI-052 in asthma patients. This advancement indicates the company's focus on developing new treatments and expanding its therapeu", "url": "https://www.msn.com/en-us/health/other/aclaris-therapeutics-maps-busy-pipeline-calendar-plans-phase-2-asthma-trial-for-ati-052/ar-AA24RxAc", "source_name": "MSN", "published_at": "2026-06-07T00:10:08", "published_display": "07 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC", "summary": "Aclaris Therapeutics, Inc. (NASDAQ: ACRS) held its 2026 annual meeting where shareholders re-elected two directors, Anand Mehra, M.D. and Maxine Gowen, Ph.D., to serve until the 2029 annual meeting. They also approved the compensation of the company\u2019s named executive officers on ", "url": "https://www.stocktitan.net/sec-filings/ACRS/8-k-aclaris-therapeutics-inc-reports-material-event-63b2c783ee08.html", "source_name": "Stock Titan", "published_at": "2026-06-05T12:10:22", "published_display": "05 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital", "summary": "LifeSci Capital has set a price target of $13.00 per share for Aclaris Therapeutics (NASDAQ: ACRS). This announcement provides investors with an analyst's valuation perspective on the biopharmaceutical company. Investors may consider this price target in their evaluation of Aclar", "url": "https://www.moomoo.com/news/post/70947668/aclaris-therapeutics-price-target-announced-at-13-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-03T09:40:39", "published_display": "03 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform'", "summary": "LifeSci Capital initiated coverage on Aclaris Therapeutics (ACRS) with an 'Outperform' rating and a $13.00 price target, signaling a positive outlook for the biopharmaceutical company. Despite this, GuruFocus assesses ACRS as significantly overvalued with a GF Value\u2122 of $0.46 aga", "url": "https://www.gurufocus.com/news/8896767/acrs-initiated-coverage-by-lifesci-capital-rating-outperform?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-03T03:40:39", "published_display": "03 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 PM ET. CEO Dr. Neal Walker and other senior leaders will host a fireside chat, which will be webcast live and archived on the company'", "url": "https://investingnews.com/aclaris-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference/", "source_name": "Investing News Network", "published_at": "2026-05-28T14:39:39", "published_display": "28 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $10.2, Implies 126% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNdzB2TmtSZHE2am1aWlZJV1prbXlPNkdHdFk2M2Nid2JQekJUOXBnSk9lNmNuMkhnaEFHSEhNOXhjNkZfTktIYjJuQXl0LVJVdl95b3QzU2RWRDJyeGFnREgtaUVmdm9MUkZteXNVRGo0dXB1bEZYYUlpSThJUW9BMWo1M2Uyc2NnbUN3dUV2aGFFdjZER2piWHRFSVhnRjFLNFFiVjYwNFppSFV0X29tbVB6LWE2QUh0Zzlib0FPQUp3cGRqck8tRjRnNFhBNnZsSlBtVEdocmFwM1JzOFpKYUNR?oc=5", "source_name": "TradingView", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Expands Immunology Pipeline Ahead of Key Trial Data", "summary": "Aclaris Therapeutics (Nasdaq: ACRS) is advancing its immunology pipeline with several mid- and late-stage clinical milestones expected this year. The company anticipates topline data for ATI-052 in asthma and atopic dermatitis and bosakitug in atopic dermatitis in the second half", "url": "https://www.mychesco.com/a/news/business/aclaris-expands-immunology-pipeline-ahead-of-key-trial-data/", "source_name": "MyChesCo", "published_at": "2026-05-16T16:40:11", "published_display": "16 May 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding", "summary": "Aclaris Therapeutics, Inc. (ACRS) is advancing multiple late-stage immunology assets, including biologics and small molecules targeting dermatologic and respiratory diseases, towards key milestones in 2024. The company's pipeline features anti-TSLP and ITK inhibitors, and it expe", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3330427:0-acrs-multiple-late-stage-immunology-assets-advance-toward-key-2024-milestones-backed-by-robust-funding/", "source_name": "TradingView", "published_at": "2026-05-14T17:09:09", "published_display": "14 May 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026", "summary": "Aclaris Therapeutics (ACRS) is progressing three novel compounds through clinical trials, targeting significant, underserved inflammatory and immunological (I&I) markets. These compounds, comprising both oral and biologic therapies, have demonstrated strong efficacy and safety. M", "url": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3330220:0-acrs-multiple-innovative-i-i-therapies-advance-toward-key-phase-2b-milestones-in-2026/", "source_name": "TradingView", "published_at": "2026-05-14T16:09:09", "published_display": "14 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQYjRlcEoycDlIYzhLOWFxLUxRbFJxdE9OUktSU0gzVENaVGZNSzhUQWF4eHltQXRZb3hDSm12amVrdkFFd2J6dHNZTFRuelc4b3JPdU1uRlVwZ0xmQzZpSDZHTzBlbDNtVHpxdV9wZ3ljdjBsUHBRLVF6VHNNQm5KZlh6MWZNNkw4ZHJDT2w0Z25KRWpUWkQ0V1JycWtKMkhzdkYtUjlMRkY0ZjhJVmhhSw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) Quarterly Loss Near US$20 Million Reinforces Bearish Earnings Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aclaris-q1-earnings-snapshot-110757979.html", "source_name": "Associated Press", "published_at": "2026-05-07T11:07:57+00:00", "published_display": "07 May 2026 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aclaris-therapeutics-reports-first-quarter-105900970.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T10:59:00+00:00", "published_display": "07 May 2026 10:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNXpFU2NzVTR5bXNLTVN5em4yR0V6UGtEaU5vTlhhdUQtbElvUV9iQWhZdHhFQ2ZVSGZMWWhpMWNrNE1LaEVpWDF5cEdkcUkwLVNnY2pETFA1VlFkSWNXYVdvdmNBTnJUbktOWXNFVm5UdWtjRGZ1Z0N1T0t3dU9PNUZDb0h4QkhYSmY1N2FvMm1BaF9TcDU4QXBXc0dqb3dVZFoxVXJkWGQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSzVOeENvM1lfUjkwUUhoMExmcXlxWmUtS1U3OGVWWWdOWFk1VDVNUzg2XzRkVV8xUVZvVVRMZFVXNkxxaEY4ZGRzWEdEZHNVSURCb0hxYXJkUGRiOElaY1hya2lfMC1icFcycHNRTm1JWVlaSEZNXzNNaVdsdGZlU1FGNDM5cXp0THBQRmRKRHV2NmtuaFhUQ29PUkg1LWJtcTNOamNhRjhTMnM?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQMUhVbVluZFRzUG1XZUhZaFJOX0lEVkV0d2tUeE92Tl9haDBqWUx0eEVDUGRING1RSUEwUUVpZEtfX0syeGhRSHlKbm1sUS1leW5Md0FSNWo2cENrQm95bXdTRFVsdWp1TGtUdFlmTW5oWEFLWDZTcnUwQ24zOUZEMDlZdE9wZHVrMDhMcGV0em1zZDBuNHVZTDNoX2IxNzZjZHBQN05tSjZ5WnZvQTJ0STJhMkx1ejYtWWFRbE9kSldoZkZVSV93?oc=5", "source_name": "Investing.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of Life", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxOTDdZekxqRzcxeXNGeE13cFkxZkRLVklHaWZDWUYxcXJ4M3MwRXFaZkU4T2RNYXh4WG0tV1E2UDRpRDA5Qm10dy0zTFkwY1J6QW1RbnFoOFJJRGRQQXBsUXFrRXNWSS1iSXNqejNpczM1Znl4MDBPdm5CcXJzSU5ZNW5uUjZQSkJ1Z0hhYjVkRTZFVW5GdmRycERRTXVDREZiN3RBRE9QbUM5c21kYnlqdnBabEUtbWtrbXAwT29WRFM1SVphVVdfY0xfUFFsWGYzVHlaT29hSmtpcDNyM044UDg0WUxsQUtvU2ZhYXpPNXlVbmVSYi10ZnpzVVhRX0xJVkdxY2pUMVRNMXJtbDhYXzhUMEFxbkVHNkw2bWVWTXhTRTU2Nm9wNHRGMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNS0d2RWJVMk9CSFJCdXlNVV9Rb1pPYmdDQWl4N3R3Mi1nUEZUbmV3MGlMRzhmeDR6aFVONWNYT2tGcU1fd01Pb2VYQnJrMHVzdE42Rjg5akI0aUFOTUlMUV9LZGRUYXc5NDVNelBRV3hUS2NLcDJKdk5YVUtYVTlRbkVwcw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOU05hb29UajNidmlUNHdLMElpaW8zcDRleFN2Q0ZPY0tYN21OdEFpN1hfZEhaV0xNTllLWjlBQVFSWW9mdkFKdU1XeWVuV0pjTTNkMU5OcmlES3FrZzJ3RlNxYi1hLUVlTWV4bEVBdlVvSm0tc2dnckN2WjllMWdLSkRkUWNWZHU5LXlnUkNodWQyMU5DTVlsQlhIcWZiZldlQzdtRHhPU1JaSWdWV013TFRGa1pMM3Y3Y1dCZUE4aDhQNDc3Z092RWJR?oc=5", "source_name": "TradingView", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZmNQSmtyOTZPTFluUF9ZWUkyZDIyelFqQ01rdTEwRDVkV2VhV1JCd19UVUlkZHhySG1XSmVPS1NKcktZT3BEYWVXYXN5ekFoY2V0RWhNRWpob3ZhMm1RdkVPM1JQMWtpSmQzaWFuMkdQcGpIc1hPVmdzR09qSjM2Y2NHOHQxMUl6bkVXbnFxU3Yyek9ncjdZQTAxZzdrT1BxWWEtWERYLTIwVk5GaGMyc3lqVjFzUFg4Qks1MVNpSmNUOXJXa2x3QW1GRElBRnpEc0RyQ1dVWnhyTU1POXM3NF9vcEZFeXY3NVHSAe8BQVVfeXFMTXltY0hSMmtiSVNpbnlISWxGY1pud0U2VTl5VV8zSlQyVTIyVjBxX0tsRnJHQ2ZJMEJmS041Q1NZZUp0MTlfREE0UVlHU0ZONjQ3VHhvZlA5T2ptOXZYMW5mZWk2Q1NXbVgzVm52Zmh0VXp3YUtVaW9DNGZLRkdVY2wybnJFdVpYcldUTUtoNFRKa25EN1pFc1NUMGxvbk1QcmhrNkRHNjljUUdmSTVpc1dSVE9ySUR2VVVhOFpiRUNrV0M0Y2lPdVZPVmlZc1E3dUlpd0wxS3lsQXNnS1JUVVJiUU5WY2FlYmt0bm1VY28?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow (NASDAQ:ACRS) 2026-01-06", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNT3NrbTdaSTI2allPYzhCSlpWUy1WSTI2QkRqekVXRDVPbURHb3Jyb1FOT1h5WTRiaUFORkZqTVhmckVmaXFZc3FxT1NZcDNMN0RmSkFNOW9XV25vMzUwcEktbnQ2Sk90RHY0NjI2cGNZQWVPeWwwTGVqeUJYYWEtZHhQZ3lmN0FoRWJISE5Ccjg5VFVDNTN2MGdMWmFqemFGUmNXU1lXUV8wQ2oweGRwWnVOSFZTZkYzNmYwNjI2dlhiTXZxVWRLV0k4b3o?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Aclaris Therapeutics Stock Hold Up When Markets Turn?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOT3ZhcmxlQnVtWXc1dmdmWnJqNUVIR0JTSTY5RjVUeUxCcVYwNHdUQ0VaVzhXZHVGODdNRjZwaVBtZ3Q4eE5EMlotRzV0TFdXUXBaY1E2MHBmc2pGak9KTFZwWEY1anBmVzAtVUZUOUM2MTdEcHhWeGtlMlJFNXhsc3ZjcmM4ZkpyVElMQkd2OXVyeFNVSllrM1pBX3R5bGpOZW9ZMjFoc0dLTnQ5ZDkyeHhQZ09tN1l0bDBDcVFncUlqM01SdlE?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPVXdwXzdtVVFQeW5ld2d6Q00xZ0ZIV1pFZW11eDB1STM1ZFNBLThIZjNDRmZRY1RGdzl5QXlxVXlpTVY2UVdWLUJBdHgxd2p3QkdYRU12QlpVd1RoTHdyVUtDS2tvVXpoS2JqaUJSZXQxSDFBcXhfY2RtTmtzb3YtMlNWUlFfQzJ6QUlDbktDOWpFNUJNbFNSc0xRX0JiZVpTbmVsMmFLdkRQNDhZZzZJZS11VFhZZjlRWW52NlFVbDVNTm9PblhjU3E5Z01oVmFSWldRRXIzZWRJanU2Qk1j?oc=5", "source_name": "BioPharma APAC", "published_at": "2024-11-19T08:00:00+00:00", "published_display": "19 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics Secures $80 Million in Private Placement of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOdEVOTW9CRGQ0NE5yTWNrQTBEUElCc3ZFQTJuTjl0aEJGcWZJSnFzTmlRajltcFV2enJHZ2EwZmRMcTZLdGpzZl93TUFYcFJCMVlZTDZqb19rLVUtQUJYSThqMEV0OVgxajJELVU2UVRLU3lBNWMxSjlUN0Y3ejk4VmIyT25QTkRqcExBTjNfb3VsY2RRRzJWZ3R1WDYtbV9GTWVieVpBTFY1UFN6UlNTa01n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-11-18T08:00:00+00:00", "published_display": "18 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACRS Stock Price and Chart \u2014 NASDAQ:ACRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1VUWlFQzNzcGo1N1R0THFMSWZVWnpLTFVKV2JaYjVsZnVEM1VDSVJlLXNWN3JnNkRucjMxdU1nNFd1dUliSnhaR1Q3aUQ4RDVBWXdERDFUZ0lacjJz?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T08:30:47+00:00", "published_display": "21 Jul 2017 08:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $ACRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE14cHlpejJyY2hZam9razF1NXVpZGZpdFBoMXdtS3dEREhaR2dlWUJmSGhUa0tjMUprRERab3MwZUZaUlBqamZLbzhja0ZQQzZ1TmdfMHdtZkk5Zw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T01:44:29+00:00", "published_display": "12 Aug 2016 01:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 59, "sentiment_summary": {"positive": 19, "negative": 4, "neutral": 36, "score": 56, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 11.56, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 5.58, "latest_week": "2026-07-10", "one_week_move": 0.4, "four_week_move": 29.2, "twelve_week_move": 31.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.132579, "market_dynamics_buy_signal": false, "relative_strength": 54.112359, "fair_value_gap": 107.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.9908, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.4% over one week, +29.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Market source", "count": 9}, {"label": "TradingKey", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Stock Titan", "count": 3}, {"label": "marketscreener.com", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.4% over one week, +29.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris"}], "updated_at": "2026-07-17T00:23:35.555694+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}